Citizens JMP lowered the firm’s price target on Prothena (PRTA) to $78 from $80 and keeps an Outperform rating on the shares. Prothena reported Q1 financial results and provided a business update, reiterating timelines for key clinical readouts in 2025. The firm says the stock is “compelling” ahead of the Phase 3 results for birtamimab in AL amyloidosis and PRX012 in Alzheimer’s disease.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA: